The combination of Bortezomib with FKB for enhanced anti-prostate cancer effects is also mechanistically or rationally justified, given that Bortezomib and FKB act through two distinct mechanisms for down-regulation of Skp2 expression: one is through suppression of transcription and the other is through protein ubiquitination and degradation. Here, SKP2 is linked to prostate cancer.